drugset / Trial / NCT03743194

Pectoralis and Serratus Muscle Blocks

NCT03743194 ↗

Phase 4 Completed 210 enrolled The Cleveland Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

The overall research plan is PECS/SAP blocks with liposomal bupivacaine improve the Overall Benefit Analgesia Score averaged over the postoperative days 1, 2, and 3. A 20% reduction on geometric means (i.e., true ratio of geometric means of 0.80) in OBAS will be considered the minimal clinically important benefit.

Timeline

Start
2021-12-14
Primary completion
2022-02-28
Completion
2022-03-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 266 mg Other
Comparator Bupivacaine Other / unclassified — Other

Indications

No indication recorded.